Nothing from AASLD leads me to think Boceprevir has narrowed the gap relative to Telaprevir. MRK needs to find a sustainable marketing angle to avert having Boceprevir become a commercial bust. Comments?
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.